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Despite considerable progress in recent years, the overall prognosis ofmetastaticmalignantmelanoma remains poor,
and curative therapeutic options are lacking. Therefore, better understanding of molecular mechanisms underlying
melanoma progression and metastasis, as well as identification of novel therapeutic targets that allow inhibition of
metastatic spread, are urgently required. The current study provides evidence for aberrant cyclin-dependent kinase 5
(CDK5) activation in primary andmetastatic melanoma lesions by overexpression of its activator protein CDK5R1/p35.
Moreover, using melanoma in vitro model systems, shRNA-mediated inducible knockdown of CDK5 was found to
cause marked inhibition of cell motility, invasiveness, and anchorage-independent growth, while at the same time net
cell growthwas not affected. In vivo, CDK5 knockdown inhibited growth of orthotopic xenografts as well as formation
of lung and liver colonies in xenogenic injectionmodelsmimicking systemicmetastases. Inhibition of lungmetastasis
was further validated in a syngenicmurinemelanomamodel. CDK5 knockdownwas accompanied by dephosphorylation
and overexpression of caldesmon, and concomitant caldesmon knockdown rescued cell motility and proinvasive
phenotype. Finally, it was found that pharmacological inhibition of CDK5 activity bymeans of roscovitine aswell as by a
novel small molecule CDK5-inhibitor, N-(5-isopropylthiazol-2-yl)-3-phenylpropanamide, similarly caused marked
inhibition of invasion/migration, colony formation, and anchorage-independent growth of melanoma cells. Thus,
experimental data presented here provide strong evidence for a crucial role of aberrantly activated CDK5 inmelanoma
progression and metastasis and establish CDK5 as promising target for therapeutic intervention.
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Malignant melanoma is the seventh most common newly diagnosed
cancer in women and the fifth most common in men in the Western
world. Incidence rates for melanoma are increasing, as opposed to
stable or declining trends observed in most other cancer types [1].
Over the past years, considerable progress has been made in the
treatment of advanced, metastatic disease stages with the advent of
novel immunotherapeutic strategies and targeted therapies [2–4].
Nevertheless, metastatic melanoma still carries an extremely poor
overall prognosis, and curative strategies are still lacking [5]. Despite
the prominent role metastasis plays for melanoma patients from a
clinical point of view, all attempts to therapeutically prevent
metastatic spread have been futile so far. Therefore, better
understanding of the pathophysiological mechanisms underlyingmelanoma progression and metastasis on a molecular level and
identification of potential druggable targets to prevent these processes
are urgently required.
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crucially involved in regulating neuronal migration during brain
development [6]. Increasing evidence is being accumulated only in
recent years suggesting additional functions of CDK5 outside the
nervous system [7,8]. Of interest, studies from our own group as well
as by others suggest that similarities exist between early neuronal
migration during embryogenesis and metastatic spread of malignant
tumors. It was hypothesized that CDK5 modulates oncogenic
signaling pathways involved in conferring a prometastatic, invasive
phenotype and might be a suitable therapeutic target that could allow
to specifically preventmetastatic tumor spread in certain entities [9–11].
This current study examines the role of CDK5 and possible effectors
involved in progression and metastatic spread of malignant melanoma
using primary tissue samples as well as relevant functional in vitro and
in vivo model systems.
Materials and Methods
Cell Culture
Human melanoma cell lines A375, SKmel28, FM8, Mel1479, and
DO8 and murine cell lines B16F10 and 1274mel were cultured in
RPMI1640 media (PAA Laboratories, Pasching, Austria) supple-
mented with 10% FBS, 1× penicillin/streptomycin (PAA Laborato-
ries), and 5 μg/mL plasmocin (InvivoGen, San Diego, CA). 293 FT
cells were maintained in DMEM containing 10% FBS, 0.1 mM
nonessential amino acids, 1 mM sodium pyruvate, and 1× penicillin/
streptomycin (all PAA Laboratories) as well as 5 μg/mL plasmocin
(InvivoGen). All the cell lines were grown in a humidified atmosphere
at 37°C in the presence of 5% CO2 and were routinely tested for
mycoplasma infection using a polymerase chain reaction(PCR)–based
assay as described elsewhere [12].
Lentivirus Production and Generation of Stable Cell Lines
To generate stable cell lines, a target set of shRNA sequences
directed against human CDK5 in an inducible pTRIPZ-Tet-On
expression vector system (Thermo Scientific, Waltham, MA) was
used. Clones that showed more than 90% knockdown efficiency in
the presence of doxycycline were used for further experiments and
designated as CDK5-shRNA#F10 (Clone ID-V3THS 390940) and
CDK5-shRNA#B7 (Clone ID-V3THS 390939). For murine cell
lines, a target set of shRNA sequences against murine CDK5 in
pGIPZ expression vector system was also obtained from Thermo
Scientific, and the clone showing efficient knockdown was used and
designated as murine CDK5shRNA#1 (Clone ID-V2LMM 2408).
Empty vectors, pTRIPZ and pGIPZ, respectively, containing no
shRNA inserts were used as negative controls.
For lentivirus production, 293FT-packaging cells were co-transfected
with pCMV-VSVg, pCMV-dR8.74, and the respective pTRIPZ and
pGIPZ plasmids using calcium phosphate method as previously
mentioned [13]. Supernatant containing lentivirus was harvested after
48 and 72 hours and used to transduce human or murine melanoma
cell lines. Resistant clones were selected and maintained in the presence
of puromycin (2 μg/ml) throughout all in vitro experiments.
Cell Viability (3-(4,5-Dimethyl-2-yl)-5-(3-Carboxymethoxyphenyl)-
2-(4-Sulfophenyl)-2H-Tetrazolium) Assays
Cell viability was determined using 3-(4,5-dimethyl-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
assay as previously described [14]. Briefly, 2000 cells per well wereplated in full growth media with or without doxycycline (2 μg/ml) for
0, 24, 48, and 72 hours, respectively. At each time point, the assay was
terminated and relative cell growth was determined using the CellTiter
96 reagent (Promega, Madison, WI), as recommended in the
manufacturer's protocol. All experiments were set up in triplicates,
and the results were normalized to the mean cell viability at 0 hours.
Soft Agar Assays
Soft agar assays were set up in six-well plates as described previously
[15]. In brief, a base agar layer was formed bymixing 2 ml of media and
1% agarose on top of which a second layer of 2 ml of media containing
0.7% agarose and 10,000 cells was poured and allowed to solidify.
Finally, 2 ml of media was added on top of the agarose layers, and the
plates were incubated at 37°C for 4 weeks. When colonies became
visible, cells were stained with 0.005% (w/v) crystal violet solution
(Sigma Aldrich, Steinheim, Germany) and visualized by trans-UV
illumination (BioRad, Hercules, CA). Colonies were counted, and
colony counts were normalized to the mean colony count of the
respective uninduced controls. All assays were set up in triplicates.
Cell Motility Assays
To test the effect of CDK5 knockdown on motility of melanoma
cells, wound-healing assays were performed using fibronectin-coated
plates. Stably transfected cells were grown to near confluency in
24-well plates coated with fibronectin (25 μg/well). A scratch was
made using a pipette tip, cell debris was removed by washing twice
with PBS, and further media was added to cells. Light microscopic
images were taken at 0 and 22 hours, respectively.
Invasion Assays
To determine the invasive potential of cells, Boyden chambers with
8 µm pore size filters coated with Matrigel (50 μg per chamber; BD
Biosciences, San Jose, CA) were used. A total of 30,000 cells/well were
placed in the upper chamber and incubated at 37°C for 72 hours, at
which time cells that had invaded to the lower side of the filter were fixed
in 70% ethanol and stained with hematoxylin and eosin (H&E).
Membranes were then mounted onto glass slides and examined
microscopically. Cells were counted in five randomly selected
microscopic fields, and means and standard deviations were calculated.
Western Blot
Cells were lysed using radioimmunoprecipitation assay buffer (1%
Igepal CA630, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM EDTA)
supplemented with protease and phosphatase inhibitor cocktails (Sigma
Aldrich). Fifty micrograms of total protein was separated using 4% to
12% Nupage bis-tris gels (Life Technologies, Darmstadt, Germany)
and transferred onto PVDFmembranes (Millipore, Billerica,MA). The
blots were blocked using either 5% (w/v) BSA or 5% (w/v) milk in
TBST for 1 hour and then later probed using primary antibodies
against CDK5R1p35, CDK5, caldesmon, GAPDH (all used at a
dilution of 1:1000; Cell Signaling,Danvers,MA) or phospho-caldesmon
(Tyr27) (1:500; Santa Cruz Biotechnology, Dallas, TX) as well as
HRP-coupled secondary antibodies directed against rabbit or mouse
IgG, respectively (1:2000, Cell Signaling). Detection was performed as
previously described [16].
RNA Extraction and Reverse Transcription Quantitative PCR
For quantitative real-time reverse transcription (RT)–PCR analy-
sis, cells were lysed and total RNA was extracted using RNeasy mini
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RNA was reverse transcribed using random primers and the High
Capacity cDNA Reverse Transcription Kit (Life Technologies)
according to the manufacturer’s specifications. Real-time quantitative
PCR for human CDK5 and caldesmon was performed using the SYBR
Premix Ex Taq (Tli RNase H Plus) kit (TaKaRa Bio Europe,
Saint-Germain-enLaye, France) on a Realplex2 Mastercycler Real-time
PCR System (Eppendorf, Hamburg, Germany). Relative fold levels were
determined using the 2(−DeltaDeltaCt) method [17], with GAPDH used
as housekeeping control.
Orthotopic Xenograft Experiments
Animal experiments described were approved by the government
of the state of North Rhine-Westphalia. Mice were maintained
according to the guidelines of the Federation of European Laboratory
Animal Science Associations. Orthotopic xenografts were generated
by injecting 2.5 × 106 CDK5-F10 cells intradermally suspended in a
total volume of 200 μl [PBS/Matrigel (BD Biosciences), 1:1 (v/v),
prechilled to 4°C] into 6- to 8-week-old immunodeficient HPRT
NOD-SCID mice (Jackson Laboratory, Maine, USA). After 2 weeks,
subcutaneous tumor volumes were measured using digital calipers
(Milomex, Pulloxhill, UK) and calculated using V = 1/2(ab2), where
a is the longest and b is the shortest orthogonal tumor diameter [18].
Mice were then randomized and divided into two cohorts, one where
mice received doxycycline (0.2 mg/ml) in drinking water containing
2.5% (w/v) sucrose to induce CDK5 knockdown in vivo and the
control group where mice received only 2.5% (w/v) sucrose in
drinking water. Tumor volumes and body weights were measured
once weekly. After 5 weeks, tumors were harvested, and samples were
snap-frozen or fixed in 10% buffered formalin for further analyses.
In vivo Lung Colonization Experiments
For this experimental metastasis assay, 6- to 8-week-old male
immunodeficient HPRT NOD-SCID mice were used. First, 1 × 106
CDK5-F10 cells resuspended in 200 μl PBS were injected in the lateral
tail vein. The group of mice designated CDK5-F10 (+dox) group was
maintained on doxycycline (0.2 mg/ml), whereas the second group,
designated CDK5-F10 (−dox), received water supplemented with
sucrose only. After 10 weeks, mice were euthanized, and organs were
harvested, fixed in 10% buffered formalin, and paraffin embedded.
Hematoxylin-stained tissue sections were then evaluated histologically
for the absence or presence of colonies formed by disseminated cancer
cells within lungs and liver.
Syngenic Injection Model
Similarly, lung colonization assays were also done using an
immunocompetent syngenic B16 murine model of melanoma.
Briefly, 100,000 B16-shCDK5 and B16-shScr cells resuspended in
200 μl of PBS were injected in the tail vein of C57BL/6 mice. After
21 days, mice were euthanized, and the lungs and livers were fixed
and paraffin embedded for further histological evaluation.
Phalloidin Staining
A total of 50,000 doxycycline-induced or -uninduced, stably
transduced SKmel28 cells (clones F10 and B7) were seeded and
grown on fibronectin (25 μg/ml)-coated 15-mm glass cover slips for
24 hours. On the next day, cells were washed with PBS and fixed with
4% formaldehyde for 20 minutes at room temperature. Cells were then
permeabilized using 0.2%Triton X-100 (Sigma Aldrich) for 5 minutesfollowed by three washing steps with PBS. Fixed and permeabilized cells
were then incubated with FITC-conjugated phalloidin (1:1000, Life
Technologies) for 30 minutes at room temperature. Hoechst 33342
(Life Technologies) at a concentration of 1 μg/ml was used for staining
of nuclei. Stained cells were then washed with PBS and mounted on
glass slides using DAKO mounting medium. Images were captured
using fluorescence microscopy.
Kinase Activity Assays
CDK5 kinase assays were performed as previously described
elsewhere [10].
Statistical Analysis
Kruskal-Wallis analyses were carried out using SPSS version 11.0.1
for Microsoft Windows; two-tailed Student’s t test andMann-Whitney
U test were performed using GraphPad Prism for Windows version 6.
P b .05 was regarded as statistically significant. Unless indicated
otherwise, results are shown as mean ± SD.
Results
Overexpression of CDK5 and its functional Activator
CDK5R1/p35 in Human Melanoma
CDK5 has been described as ubiquitously expressed in mammalian
tissues including melanoma cells [19], with its functional activity
being regulated by and strictly dependent on its association with
either one of its two activator proteins, CDK5R1/p35 or CDK5R2/
p39, respectively. In other words, expression of either CDK5R1/p35
or CDK5R2/p39 is equivalent to CDK5 activation throughout
various tissues [9,20–22]. Therefore, we evaluated p35 expression in
human melanoma cells and primary tissue samples. Firstly, tissue
microarrays (US Biomax, Inc., Rockville, MD) representing 86 cases
of primary malignant melanoma lesions, 50 samples of melanoma
metastases, and 27 control samples of normal skin tissue, with up to 3
replicates for each of the total 163 cases, were stained for p35
expression using immunohistochemistry. Each sample was scored as 0
(negative), 1+, 2+, or 3+ based on cytoplasmatic p35 immunolabel-
ing; in cases with different values among replicate samples, the highest
value was counted. Overexpression of p35 as compared with normal
skin samples was found in 70% of melanoma tissues tested, including
both primary and metastatic lesions. Thirty-six percent (49/136 cases)
of melanomas (34 of 86 primary and 15 out of 50 metastatic lesions,
respectively) showed high protein expression scored as “3+” as
compared with basal immunolabeling (0 to 1+) observed in 100%
(27 of 27 informative cases) of normal skin tissues. Intermediate
(scored as “2+”) expression was found in 34% (46/136 cases) of
melanoma samples (31/86 primary and 15/50 metastatic melanoma
lesions, respectively) but in none of the non-neoplastic normal skin
control samples (Figure 1, A and B).
Next, we evaluated whether CDK5 activation by expression of p35
could be confirmed in melanoma cell lines cultured in vitro as well.
Of note, constant strong basal protein expression of CDK5 was
confirmed in all five melanoma cell lines (A375, SKMel28, FM8,
Mel1479, DO8) tested in Western blot analyses, whereas expression
of the CDK5-activator p35 and its cleavage product p25 was detected
in four of five cell lines with considerable differences in basal
expression levels. The highest steady-state expression levels were
found in SKMel28 cells, which were therefore chosen for subsequent
knockdown experiments (Figure 1C ).
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Colony Formation and Anchorage-Independent Growth of
Melanoma Cells In Vitro
To study the role of CDK5 in melanoma progression and
metastasis, CDK5 function was abrogated using short hairpin RNA
interference inmelanoma cells. An inducible lentiviral pTRIPZ-Tet-On
vector system was used for this purpose in which expression of shRNA is
induced in the presence of doxycycline; red fluorescent protein served
as control of transduction efficiency. SKMel28 melanoma cells were
stably transduced with one of two independent CDK5-specific shRNA
clones (designated “SKMel-F10” or “SKMel-B7,” respectively) or with
empty pTRIPZ vector as mock control. Transduction efficiency and
specificity of doxycycline induction were tested using fluorescence
microscopy (Figure 2A). Western blot analysis and quantitative
real-time RT-PCR showed successful and reproducible knockdown
of CDK5 upon addition of doxycycline in SKMel-F10 and
SKMel-B7 mass clones at both the protein and mRNA level, but
not in mock-transduced vector-only controls or in the absence of
doxycycline (Figure 2B).
Of note, knockdown of CDK5 did not show any major effect on
net cell growth of either of the tested melanoma cell clones for up to
72 hours in MTS assays, in line with previous reports stating that
CDK5 is not directly involved in regulation of cell cycle progression
(Figure 2C ). As opposed to this, however, a rather pronounced effect
of CDK5 knockdown on colony formation and anchorage-independent
growth of SKMel melanoma cells was observed. Whereas addition of
doxycycline did not affect colony formation of mock-transducedA
B
Figure 1. Expression of CDK5 and its activator protein CDK5R1/p35 in
to be overexpressed in primary melanoma as well as in metastatic le
(B) In tissue microarrays, intermediate (2+) or high (3+) p35 immun
tissue as compared with benign skin. (C) Western blot analysis of
melanoma cell lines.cells, marked inhibition was found in both SKMel-F10 and
SKMel-B7 when comparing induced, shRNA-expressing cells to
uninduced controls without addition of doxycycline. Moreover,
colonies formed in SKMel-F10 or -B7 after CDK5 knockdown were
found to be not only significantly fewer in numbers (reduction of
colony counts by more than 90%) but also much smaller in average
size (Figure 2D).
Suppression of CDK5 Impairs Migration and Invasiveness of
Human Melanoma Cells
Cell motility and invasion are indispensable prerequisites for tumor
progression and metastasis. CDK5 activation is known to be required
for neuronal migration during brain development. Therefore, the
potential role of CDK5 in cell motility and invasiveness of melanoma
cells was studied using established in vitro model systems. Firstly,
wound-healing assays were performed in near confluent monolayers
of SKMel28 clones containing inducible CDK5-specific shRNA as
described above, both in the presence or in the absence of
doxycycline, respectively. Again, mock-transduced clones were
included as additional controls alongside each set of experiments.
The ability of cells to close the wound area was compared at 0 and
22 h. Of interest, mock controls as well as uninduced SKMel-F10
and SKMel-B7 clones migrated much faster into the scratch area and
thus promoted quick closure of the wound gap as compared with
their respective doxycycline-induced counterparts, thereby confir-
ming the inhibitory effects of CDK5 knockdown on melanoma cell
motility (Figure 3A). Migration and invasiveness were then assessed inC
humanmelanoma tissues and cell lines. (A) CDK5R1/p35 was found
sions as compared with normal skin using immunohistochemistry.
olabeling was more commonly observed in malignant melanoma
CDK5, p35, and p25 steady-state expression levels in five human
Figure 2. shRNA-mediated knockdown of endogenous CDK5 inhibits anchorage-independent growth of melanoma cells. An inducible
pTRIPZ-Tet-On expression vector system containing CDK5-specific shRNAwas used to knock down CDK5 expression in SKMel28 human
malignant melanoma cells. (A) Transduction efficiency was confirmed by red fluorescent protein expression as visualized using
fluorescence microscopy. (B) Successful inducible CDK5 knockdown was checked using Western blot analysis (upper panel) and
quantitative real-time RT-PCR analysis (lower panel) both in the absence and in the presence of doxycycline, respectively. (C) Inducible
knockdown of CDK5 did not show any significant effect on the net cell growth of SKMel28 cells as assessed using MTS assay. The figure
shows results of two different pairs of mass clones (designated “SKMel28-F10” and SKMel28-B7” with their respective mock controls)
both in the presence (=induced state) and in the absence (=uninduced state) of doxycycline. (D) In contrast, colony formation and
anchorage-independent growth in soft agar were significantly reduced in both SKMel28 mass clones when induced by doxycycline as
compared with uninduced or mock-transduced controls. Colony counts are plotted as means and SD from three independent
experiments; *P b .05.
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SKMel-B7 cells or respective mock-transduced controls were plated
into the bottoms of the transwell inserts and allowed to invade
through a Matrigel layer as a surrogate for extracellular matrix, again
both in the presence and in the absence of doxycycline, over a period
of 72 hours. Notably, CDK5 knockdown led to marked reduction of
invasion/migration in this model. Doxycycline stimulation did not
have any apparent effect on mock-transduced controls, ruling out
unspecific cytotoxic effects (Figure 3B).
Loss of CDK5 Expression Affects Morphology and Adhesion of
melanoma Cells
In neuronal progenitor cells as well as in other cancer types, CDK5
depletion was found to cause significant changes in cell morphology
and to profoundly affect actin cytoskeleton reorganization [9,23,24].
Therefore, we next examined whether the observed effects on
melanoma cell migration following CDK5 knockdown might be due
to modulation of cytoskeleton reorganization as demonstrated using
immuofluorescence labeling of F-actin fibers. Both uninducedFigure 3. Abrogation of CDK5 inhibits melanoma cell motility and i
mock-transduced or CDK5-shRNA–expressing SKMel28 clones with o
migrate and close the wound area after 22 hours was compared. (B
invasion and migration through Matrigel of SKMel28 cells upon do
diagram shows relative cell counts as means and SD. **P b .01 (C) In
and impaired cytoskeleton remodeling as shown by immunofluoresc
lacked F-actin bundles and showed a loss of cell polarity in the pr
uninduced and mock-transduced clones.SKMel-F10 or B7 clones as well as mock transduced clones showed
marked cell spreading and tight attachment to fibronectin-coated
surfaces. Also, cells were more motile and regularly formed
well-defined pseudopodia. In contrast, doxycycline-induced,
CDK5-depleted cells showed randomly oriented actin fibers with
no discernible polarity, were smaller in size, and showed decreased
ability to protrude and spread on the coated surface (Figure 3C ).
Our in vitro results thus hint at a possible involvement of CDK5 in
melanoma cell motility, invasion, and cytoskeleton reorganization.
Therefore, we next tried to assess whether changes in CDK5
functional activity might play a role in melanoma progression and
metastatic spread using suitable in vivo model systems.
CDK5 Knockdown Inhibits Orthotopic Melanoma Xenograft
Growth
To generate orthotopic xenografts, 2 × 106 SKMel-F10 melanoma
cells were injected intradermally into the flanks of female
NOD-SCID mice and allowed to grow for 2 weeks, at which point
average tumor volumes reached approximately 80 mm3. Mice werenvasiveness. (A) Wound-healing assays were performed in either
r without addition of doxycycline, respectively. The ability of cells to
) Modified Boyden chamber assay revealed significantly reduced
xycycline-induced shRNA-mediated knockdown of CDK5. The bar
duced knockdown of CDK5 expression influenced cell morphology
ence labeling of F-actin by phalloidin. Both SKMel-F10 and B7 cells
esence of doxycycline, whereas no such effect was observed in
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group received doxycycline (200 μg/ml) and sucrose (2.5% w/v) in
their drinking water continuously for the following 5 weeks, whereas
the second group received only sucrose without addition of
doxycycline. Of note, the group of mice in which CDK5 knockdown
was induced (CDK5-F10 + dox) showed significantly inhibited
tumor growth as compared with uninduced controls with preserved
CDK5 expression (Figure 4A). Neither loss in body weight nor any
other signs of distress or behavioral abnormalities were observed in
mice from either of the two groups during the entire experiment.
After 5 weeks, tumors were harvested, and persistent knockdown of
CDK5 was confirmed by Western blot analysis (Figure 4B) as well as
by immunohistochemistry (Figure 4C ). Proliferation was assessed
using Ki-67 labeling, and no discernible differences were found
between the two arms, in line with in vitro data presented above.
Also, no discernible histological differences were observed between
xenografts derived from the CDK5 knockdown or control arm,
respectively (Figure 4C ).
CDK5 Knockdown Inhibits Formation of Lung and Liver
Metastases in a Murine Injection Model of Human Melanoma
Next, we aimed to further evaluate these promising in vivo data
using a complementary second in vivo model system, this time
specifically mimicking the formation of systemic metastases. For this
end, SKMel-F10 cells were injected into the tail veins of NOD-SCID
mice. CDK5 knockdown was then induced in vivo by addition of
doxycycline in drinking water, whereas uninduced mice served as
controls. Interestingly, in this scenario, CDK5 blockade almost
completely abrogated formation of lung colonies: uninducedFigure 4. Inhibition of CDK5 function through shRNA-mediated kn
xenografts. (A) Growth of orthotopic SKMel-F10 xenografts was sig
induced CDK5 knockdown was confirmed in explanted xenograft tum
Results from three representative doxycycline-induced and -unindu
stainings did not reveal any major discernible changes in th
Immunohistochemistry in harvested xenograft tumor tissues confirm
as determined by Ki-67 immunolabeling was not significantly reduceSKMel-F10 cells formed multiple pulmonary lesions in all animals
that were readily identified by gross inspection or histopathological
examination, whereas doxycycline-induced CDK5-depleted melanoma
cells yielded significantly fewer lesions of minimal size (Figure 5A).
Again, these observations were reproducible in several sets of
experiments and in line with in vitro data presented above.
Inhibition of CDK5 Activity by Means of shRNA-Mediated
Knockdown Blocks Lung Colonization Reminiscent of
Pulmonary Metastases in a Syngenic Murine Melanoma
Injection Model
To complement our experimental in vivo data obtained in
xenogenic transplantation models with immunocompromised mice,
we aimed to further validate the observed inhibition of metastatic
spread through abrogation of CDK5 in a third, syngenic in vivo
model system with fully immunocompetent wild-type mice. For this,
the murine melanoma cell line B16F10 was used, in which CDK5
knockdown was achieved using a sequence-specific shRNA
(Figure 5B). Scrambled shRNA was applied for mock transduction.
Injection of B16F10 murine melanoma cells stably transduced
with murine CDK5 shRNA (B16-CDK5#1) into tail veins of C57/
BL6 mice reproducibly led to diminished formation of pulmonary
metastases as compared with mock clones. Since the used B16 cell
line expresses high levels of melanin, these lesions were readily
visible upon gross inspection (Figure 5C ). Histopathological
examination confirmed large fulminant metastatic lesions in the
lungs of mice injected with B16-sh scrambled cells as compared
to markedly reduced lung metastases in mice injected with
B16-shCDK5#1.ockdown impairs in vivo tumorigenicity in orthotopic melanoma
nificantly inhibited upon induced CDK5 knockdown. (B) Sustained
or tissues at the end of the experiment using Western blot analysis.
ced mock-treated xenografts, respectively, are shown. (C) H&E
e tumor microarchitecture upon induced CDK5 knockdown.
ed efficient knockdown of CDK5 at the protein level; proliferation
d after CDK5 depletion.
302 Identification of a Promising Novel Therapeutic Target Bisht et al. Translational Oncology Vol. 8, No. 4, 2015Thus, consistent with the phenotypic effects observed in vitro, our
data provide strong evidence that inhibition of CDK5 is associated
with strong blockade of melanoma progression and metastasis in all of
the three in vivo model systems used here.
CDK5 Inactivation Leads to Upregulation andDephosphorylation
of Caldesmon
Activity of the actin- and calmodulin-binding protein caldesmon is
modulated via phosphorylation. In its dephosphorylated state, caldesmon
binds to and stabilizes actin filaments, inhibits cell migration, and
suppresses formation of podosomes and invadopodia [25–29]. Therefore,
a possible involvement of caldesmon in the phenotype observed in
CDK5-depleted melanoma cells as described above was examined.
Of interest, it was found that doxycycline-induced depletion of
CDK5 in either SKMel-F10 or -B7 cells led to dephosphorylation of
caldesmon while at the same time causing an increase of total
caldesmon as observed using Western blot analysis. No change in
phosphorylation status was found in uninduced SKMel-F10 or -B7
cells or in mock-transduced controls (Figure 6A).
siRNA-Mediated Knockdown of Caldesmon Rescues Cell Motility
and Invasion/Migration in CDK5-Depleted Melanoma Cells
To test whether upregulation and dephosphorylation of caldesmon
might indeed be an underlying cause of the observed phenotype inB
GAPDH
CDK5
Sc
r.
CD
K5
#1
CD
K5
#2
CD
K5
#3
CD
K5
#4
CD
K5
#5
C
A SKMel28
Figure 5. CDK5 knockdown prevents metastatic melanoma spread
metastases after intravenous injection of SKMel28 melanoma cells i
model system, doxycycline-induced shRNA-mediated CDK5 knockdo
pulmonary lesions as compared with uninduced controls (left panel)
knockdown, whereas they were readily observed in uninduced contro
tissue sections. (B) Injection of B16 murine melanoma cells into the ta
in vivo model system to validate the effect of CDK5 abrogation on
(“CDK5#1”) showed reproducible knockdown of CDK5 in B16 mur
Western blot analysis. (C) When this clone CDK5#1 was used in a
and average size of lung colonies representing pulmonary meta
mock-transfected cells (macroscopic image from two representativeCDK5-depleted melanoma cells with decreased cell motility and
invasion/migration as surrogate for an overall decrease in their
metastatic potential, rather than just a bystander effect, rescue
experiments were carried out. For this, SKmel-F10 cells were
transfected with scrambled or caldesmon-specific siRNA (siGenome
smartpool siRNA; 25 nM) and assayed for their migratory and
invasive ability using modified Boyden chamber and wound-healing
assays. Successful RNAi-mediated knockdown of caldesmon in both
doxycycline-induced and -uninduced SKmel-F10 cells was confirmed
by Western blot analysis (Figure 6B). Interestingly, in CDK5-deficient
melanoma cells, invasion and migration were significantly rescued by
caldesmon depletion as observed using modified Boyden chamber and
wound-healing assays. Invasion and migration of uninduced cells
(SKMel-F10 −dox) on the other hand were not affected when depleted
of caldesmon (“+siCald”) as compared with scrambled controls
(“+siScr”) (Figure 6, C and D).Melanoma Cell Migration/Invasion and Colony Formation Are
Readily Inhibited by Pharmacological Blockade of CDK5Activity
Having identified CDK5 as a promising molecular target for
therapeutic intervention in melanoma using genetic in vitro and
in vivo model systems as described above, we next wanted to evaluate
if these therapeutic effects could be replicated by pharmacologicalSKMel28
10x 10x
in murine dissemination models. (A) Formation of lung and liver
n immunodeficient HPRT NOD-SCID mice was determined. In this
wn led to a dramatic reduction in the average number and size of
. Liver metastases were completely abolished upon induced CDK5
ls (right panel). The figures show representative H&E stains of FFPE
il veins of C57BL/6 wild-type mice was applied as a third, syngenic
melanoma metastasis. One of five CDK5-specific shRNA-clones
ine melanoma cells as compared with scrambled controls using
tail vein injection model, a dramatic decrease in both the amount
stases was observed upon CDK5 knockdown as compared to
animals).
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molecule inhibitors was screened for their ability to bind CDK5
and block its kinase activity [30]. N-(5-isopropylthiazol-2-yl)-3-
phenylpropanamide (PJB) (Pubchem CID = 16760027) (Figure 7A)
was found to potently inhibit CDK5 activity in kinase assays
(Figure 7B), which is in line with previous observations, which had
shown an IC50 of around 64 nM for CDK5 and 98 nM for CKD2
inhibition, respectively [31,32]. For subsequent efficacy testing, PJB
was used alongside the well-established yet less specific small molecule
CDK5 inhibitor roscovitine.Figure 6. CDK5 affects melanoma invasiveness and migration thro
CDK5 causes upregulation and dephosphorylation of caldesmon in
compared with uninduced or mock-transduced cells as demonstra
knockdown of caldesmon is demonstrated in CDK5 knockdown ce
knockdown. (C) Caldesmon knockdown rescues invasiveness and mig
panel shows membranes from modified Boyden chamber assay
knockdown is rescued by concomitant siRNA-mediated knockdown
controls. Relative cell counts as means and standard deviations are
concomitant caldesmon knockdown by means of siRNA transfect
reduction in wound healing upon downregulation of CDK5 as shownOf note, and in line with data obtained from CDK5 knockdown
experiments, CDK5 inhibition with roscovitine or PJB did not have
any discernible effect on net cell viability as assessed using MTS assays
at concentrations of up to 10 μM after up to 72 hours (Figure 8A).
However, in modified Boyden chamber assays, pharmacological
CDK5 inhibition with either roscovitine or PJB led to near-complete
inhibition of invasion/migration of SKMel28 melanoma cells,
reminiscent of effects observed in the previously described genetic
model systems of CDK5 inhibition (Figure 8B). Finally, as opposed
to net cell growth as observed in MTS assays, in vitro colonyugh regulation of caldesmon. (A) shRNA-mediated knockdown of
SKMel-F10 and SKMel-B7 cells in the presence of doxycycline as
ted using Western blot analysis. (B) Successful siRNA-mediated
lls. Note that CDK5 protein levels are not affected by caldesmon
ration of CDK5-depleted SKMel human melanoma cells. The upper
s; loss of invasion/migration upon doxycycline-induced CDK5
of caldesmon, whereas no effect is found in scrambled siRNA
shown in the lower panel. *P b .05. (D) In wound-healing assays,
ion leads to increased cell motility, thus rescuing the observed
above.
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growth in soft agar were abrogated upon CDK5 inhibition by
roscovitine or PJB as well (Figure 8C ).
Of note, similar to what was seen in the genetic model, SKMel
melanoma cells treated with roscovitine or PJB also showed no
significant change (roscovitine) or a slight increase (PJB) in total
caldesmon protein levels, whereas phosphorylation of caldesmon was
decreased using either of the two compounds (Figure 8D).
Discussion
Although localized melanoma is effectively treated by local intervention
such as surgical resection or irradiation, therapeutic options and overall
prognosis for metastatic disease remain poor to date despite tangible
progress in recent years such as the advent of novel tyrosine kinase
inhibitor–based targeted or immunomodulatory therapies.
CDK5 has been well established as centrally involved in regulating
migration of neuronal progenitor cells during brain development in
embryogenesis [20,33,34], whereas extraneuronal reactivation of
CDK5 in malignant tumors has only recently been recognized. Our
data presented here provide strong experimental evidence that
activation of CDK5 by overexpression of its activator p35 mediates
invasive properties and metastatic spread in malignant melanoma and
suggest CDK5 as potential therapeutic target for therapies aimed at
inhibiting metastasis in this disease. This was shown in primary human
tissue samples as well as in cell lines derived from melanoma patients.
From a translational point of view, it has been difficult in the past to
predict clinical relevance of putative therapeutic targets based on
preclinical experimental data, possibly because specific experimental
conditions used in a particular model system can often greatly influence
the obtained results [35]. Therefore, in this present study, particular
efforts were made to corroborate the observed phenotype of decreased
invasive and migratory potential of CDK5 depletion in melanoma cells
using various redundant in vitro as well as three different in vivomodelA
B
Concentration [µM]
Figure 7. PJB as small molecule CDK5 inhibitor. (A) Chemical
structure of PJB. (B) Kinase assays show dose-dependent
inhibition of CDK5 kinase activity by PJB.systems as described above, thus increasing the chance of describing a
target that will indeed prove to be relevant in future clinical trials.
It is important to note that abrogation of CDK5 signaling through
shRNA-mediated knockdown had profound effects on melanoma cell
migration and invasion in vitro that were mirrored by loss of
metastatic potential across three different in vivo model systems used
here, while at the same time apparently not directly affecting cell
growth both in vitro and in vivo. Recently, various groups, including
our own, have begun to accumulate experimental evidence support-
ing a potential role of CDK5 in the progression of different cancers
[9,10,18]. In prostate cancer, CDK5 activity has been shown to be
involved in metastatic spread and has been suggested as possible drug
target for therapeutic intervention [10,11,36]. CDK5 is functionally
active in pancreatic cancer as well and was found to be amplified in a
subset of cases [37]. We as well as others found it to contribute to
tumor progression, and it has been suggested as a therapeutic target
that potentially allows modulation of oncogenic Kras downstream
effector signaling axes such as the RalGDS-Ral pathway [9,18,37]. Of
note, a recent study reports that inhibition of CDK5 activity in
combination with pharmacological AKT inhibition showed a
dramatic therapeutic response in preclinical animal models that led
to initiation of a phase 1 clinical trial currently evaluating this
promising novel approach in humans [38].
Likewise, increased CDK5 activity was found in hepatocellular
carcinoma, and CDK5 was identified as a potential therapeutic target
for hepatocellular carcinoma with potential synergism with DNA
damage response pathways [39].
In a recent report, CDK5 expression and activation in approxi-
mately 50% of esophageal squamous cell carcinoma samples have
been described and were linked to distinct subsets of tumors with
adverse prognosis and enhanced expression of the stem cell marker
nestin [40].
In medullary thyroid carcinoma (MTC), CDK5 activity has been
suggested to be involved in control of tumor cell proliferation through
phosphorylation and activation of STAT3 [41]. Of interest, in a more
recent study, Pozo et al. were able to show that activation of CDK5 by
C cell–specific overexpression of its activator p25, a cleavage product
of CDK5R1/p35, was sufficient to induce formation of MTC in a
conditional mouse model. Using this setup, the authors were able to
show that, in this context, aberrantly activated CDK5 signals via
retinoblastoma, thus influencing initiation and progression of MTC
[42]. Using this model, CDK5 was described as a tumor-initiating
factor and a potential therapeutic target in MTC [43].
In multiple myeloma, CDK5 has been identified as an adverse
prognostic marker and was proposed to confer resistance towards
proteasome inhibitors bortezomib and carfilzomib [44]. Moreover,
the multikinase inhibitor dinaciclib, which among others blocks
CDK5 activity with high affinity, has recently been found to be
therapeutically active as a single-agent monotherapy in highly
pretreated multiple myeloma [45]. In leukemia cells, CDK5 was
found to phosphorylate and functionally inhibit the proapoptotic
protein Noxa [46]. Of interest, CDK5 has recently been suggested to
regulate the tumor suppressor DLC1 by phosphorylation in lung
adenocarcinoma [47]. Finally, in mantle cell lymphoma samples,
CDK5 has been described as overexpressed due to promoter
hypomethylation [48].
More recently, aberrant CDK5 signaling was suggested to be
involved in migration of endothelial cells, lymphangiogenesis, and
formation of blood vessels [49,50].
Figure 8. Therapeutic in vitro efficacy testing of pharmacological inhibition of CDK5 activity. (A) MTS assays do not show any reduction in
cell viability after 72 hours upon incubation with up to 10 μM roscovitine or PJB. (B) Reduction of invasion/migration in modified Boyden
chamber assays and of (C) colony formation and anchorage-independent growth in soft agar assays upon CDK5 inhibition with roscovitine
or PJB, respectively. (D) Small molecule CDK5 inhibitors roscovitine or PJB caused dephosphorylation of caldesmon, while not affecting
total CDK5 protein levels as observed using Western blot analysis.
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roles in regulation of neuronal migration during brain development,
CDK5 is increasingly recognized as being involved in several
additional, extraneuronal pathophysiological functions. CDK5
being a highly pleiotropic protein, the studies published on this
topic, some of which are cited above, name a currently rapidly
growing number of diseases in which aberrant CDK5 activation
apparently plays a crucial role and unmask a variety of potential
underlying mechanisms and signaling pathways involved. With
respect to malignant tumors, the emerging common underlying
theme seems to be that of CDK5 being a protein kinase driving tumor
progression and metastasis across various malignancies via several
different mechanisms in a highly tissue-specific manner.
This current study for the first time provides experimental evidence
based on primary tumor samples as well as clinically relevant in vitro
and in vivo model systems for proinvasive and prometastatic effects of
activated CDK5 in melanoma cells. Moreover, phosphorylation of
caldesmon is uncovered as a potential underlying mechanism in this
case. Of note, in addition to phosphorylation of caldesmon at Tyr27
as demonstrated here, several other phosphorylation sites of
caldesmon have been previously described [51], and one might
speculate that these could also represent potential targets of CDK5,
opening up interesting avenues for future work. Caldesmon has
previously been shown to bind and thereby stabilize actin filaments,which are antagonized by cell cycle–dependent phosphorylation of
caldesmon on specific serine and threonine residues [52,53]. Tyrosine
phosphorylation of caldesmon has been found to cause its dissociation
from actin, thereby contributing to actin microfilament disassembly
[54,55]. In a recent study by Boerner et al., only phosphotyrosine-27
of caldesmon was found to be required for binding to either the
amino-terminal SH3 or central SH2 domains of Grb2 [56]. Our data
are in line with a recent report by Quintavalle et al. suggesting that
CDK5 has the potential to directly phosphorylate caldesmon in
src-3 T3 and SCC61 cells, thereby inhibiting cytoskeleton remode-
ling, formation of invadopodia, and invasive behavior [51]. The
authors of that study also conclude that CDK5 might be exploited as
a molecular target for therapeutic intervention with the potential to
block metastatic spread, similar to conclusions drawn in our own
study on CDK5 activation in malignant melanoma. Indeed, a novel
small molecule CDK5 inhibitor, PJB, was found to inhibit in vitro
melanoma cell migration/invasion, colony formation, and anchor-
age-independent growth as correlate of tumor progression. Therefore,
further studies evaluating therapeutic in vivo efficacy of this novel
compound using suitable small animal models will be of interest.
Following up on the idea to use CDK5 as drug target in melanoma
appears even more intriguing since other suitable CDK5 small
molecule inhibitors are currently already under development and or
in early clinical testing for other indications [11,45,57,58]. Therefore,
306 Identification of a Promising Novel Therapeutic Target Bisht et al. Translational Oncology Vol. 8, No. 4, 2015it is very likely that suitable drugs with known dosing schedules,
pharmacokinetics data, and toxicity profiles might soon be available,
which could then relatively easily and safely be evaluated in patients
suffering from metastatic melanoma.
Conclusion
This study provides strong experimental evidence for an involvement
of CDK5 activity in metastatic spread of malignant melanoma,
possibly via modulation of caldesmon phosphorylation. With
pharmacological CDK5 inhibitors currently already being developed
for other indications and tested with respect to their pharmacokinetics
and toxicity profiles, this might open up a viable opportunity for
therapeutic intervention aimed at blocking melanoma metastasis in
the near future.
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